COMT Protein

COMT Protein

Introduction

Pathway Diagram

```mermaid
flowchart TD
COMT["COMT Gene<br/>Catechol-O-methyltransferase"]
COMT_protein["COMT Protein<br/>Dopamine Metabolizing<br/>Enzyme"]
dopamine["Dopamine<br/>Neurotransmitter"]
cognitive_function["Cognitive Function<br/>Executive Control<br/>Working Memory"]

SLC6A3["DAT1 (SLC6A3)<br/>Dopamine Transporter"]
SLC6A2["NET (SLC6A2)<br/>Norepinephrine Transporter"]
ADRA2A["ADRA2A<br/>Alpha-2A Adrenergic<br/>Receptor"]
HTR2C["HTR2C<br/>Serotonin 2C Receptor"]

Alzheimer["Alzheimer's Disease<br/>Cognitive Decline"]
Parkinson["Parkinson's Disease<br/>Motor and Cognitive<br/>Dysfunction"]
ALS["ALS<br/>Motor Neuron<br/>Degeneration"]
Depression["Depression<br/>Mood Disorder"]
Dementia["Dementia<br/>Progressive<br/>Cognitive Loss"]

COMT -->|"encodes"| COMT_protein
COMT_protein -->|"metabolizes"| dopamine
dopamine -->|"regulates"| cognitive_function

COMT -->|"variants affect"| Alzheimer
COMT -->|"variants affect"| Parkinson
COMT -->|"contributes to"| ALS
COMT -->|"associated with"| Depression
COMT -->|"therapeutic target"| Dementia

SLC6A3 -->|"interacts with"| dopamine
SLC6A2 -->|"modulates"| COMT_protein
ADRA2A -->|"influences"| cognitive_function
HTR2C -->|"cross-regulates"| dopamine

cognitive_function -->|"impaired in"| Alzheimer
cognitive_function -->|"affected in"| Parkinson
dopamine -->|"depleted in"| Parkinson

style COMT fill:#006494
style COMT_protein fill:#006494
s

COMT Protein

Introduction

Pathway Diagram

Comt Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-protein"> [@mannisto2019]
<div class="infobox-header">COMT Protein</div> [@bilder2018]
<div class="infobox-content"> [@matsumoto2017] Gene: COMT<br> [@poewe2020] UniProt ID: P21964<br> [@williams2019] PDB ID: 1J3T, 3BWM<br> [@nackley2020] Molecular Weight: 30 kDa (S-COMT), 32 kDa (MB-COMT)<br> [@huotari2019] Subcellular Location: Cytoplasm (S-COMT), ER membrane (MB-COMT)<br> Protein Family: SAM-dependent methyltransferases
</div>
</div>

Overview

COMT (Catechol-O-Methyltransferase) is a key enzyme in catecholamine metabolism that catalyzes the methylation of dopamine, norepinephrine, and other catecholamines using S-adenosylmethionine (SAM) as a methyl donor. COMT is a major therapeutic target in Parkinson's disease, where COMT inhibitors are standard adjunct therapy to extend levodopa's half-life[@fahn2020]. The Val158Met polymorphism affects enzyme activity and is implicated in various psychiatric disorders.

Structure

Isoforms

• S-COMT (soluble): 221 aa, cytosolic enzyme, predominant in peripheral tissues
• MB-COMT (membrane-bound): 271 aa, N-terminal transmembrane helix (26 aa), more active in brain

Catalytic Domain

• SAM-binding pocket for methyl donor
• Magnesium ion (Mg²⁺) required for catalysis
• Dimeric in active form (both isoforms)

Key Residues

• Active site: D96, D141, K144 (catalysis)
• SAM binding: S119, Y68
• Substrate binding pocket: Hydrophobic region for catechol ring

Normal Function

Catecholamine Metabolism

• Dopamine → methoxytyramine
• L-DOPA → 3-O-methyldopa (major peripheral metabolite)
• Norepinephrine → normetanephrine
• Epinephrine → metanephrine

Brain Function

• Major dopamine regulator in prefrontal [cortex](/brain-regions/cortex)[@bilder2018]
• Controls synaptic dopamine levels via degradation
• Modulates catecholamine signaling timing
• Important for executive function and working memory

Enzyme Kinetics

| Substrate | Km (μM) | Vmax (relative) |
|-----------|---------|-----------------|
| Dopamine | 0.27 | 1.0 |
| L-DOPA | 3.7 | 0.6 |
| Norepinephrine | 0.14 | 0.8 |
| Epinephrine | 0.21 | 0.9 |

Expression Pattern

COMT is widely expressed:

• Brain: Highest in prefrontal cortex, [hippocampus](/brain-regions/hippocampus)[@matsumoto2017]
• Liver: Major site of peripheral metabolism
• Kidney: Important for renal catecholamine handling
• Intestine: Peripheral L-DOPA metabolism

• [Neurons](/entities/neurons) express MB-COMT
• Glial cells express S-COMT
• Prefrontal cortex: High COMT, important for dopamine regulation

Role in Disease

Parkinson's Disease

• COMT inhibitors are standard adjunct therapy[@poewe2020]
• Entacapone: Peripheral only (does not cross BBB)
• Tolcapone: Central + peripheral (requires liver monitoring)
• Extend L-DOPA half-life and reduce "wearing-off"
• Reduce motor fluctuations

Psychiatric Disorders

• Schizophrenia: Val158Met affects prefrontal function[@williams2019]
• Val/Val: Higher COMT, lower dopamine in PFC
• Met/Met: Lower COMT, better cognitive function
• Bipolar disorder: Altered COMT activity
• ADHD: Val allele may increase risk
• Anxiety/Depression: Polymorphism associations

Pain Disorders

• COMT regulates pain pathways[@nackley2020]
• Met/Met: Increased pain sensitivity
• Val/Val: Reduced pain perception
• Opioid response affected by COMT genotype

Cancer

• Estrogen metabolism links (catechol estrogens)
• Possible breast cancer risk association

Animal Models

• Comt knockout mice: Show increased catecholamine levels[@huotari2019]
• Transgenic overexpression: Reduced dopamine signaling
• Val158Met knock-in mice: Model human polymorphism
• Zebrafish: comt mutants have behavioral changes

Therapeutic Targeting

FDA-Approved Inhibitors

| Drug | Selectivity | Half-life | Daily Dosing | Notes |
|------|-------------|-----------|--------------|-------|
| Entacapone | Peripheral | 0.4h | With each L-DOPA dose | COMT-OXI |
| Tolcapone | Central + Peripheral | 2h | 3-4x daily | Requires LFT monitoring |
| Opicapone | Peripheral | 1.5-2h | Once daily | Longest duration |

Clinical Considerations

• Reduce "wearing-off" phenomenon
• May cause dyskinesias initially
• Dietary protein timing important
• Nausea is common side effect

Experimental Approaches

• Brain-penetrant COMT inhibitors
• Gene therapy approaches
• Polymorphism-guided dosing

Key Publications

See Also

• [COMT Gene](/proteins/comt-protein)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Dopamine Signaling](/mechanisms/dopaminergic-vulnerability)
• [Schizophrenia](/diseases/schizophrenia)
• [Pain Pathways](/cell-types/raphe-magnus-pain-modulation-neurons)

Background

The study of Comt Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

References